Leonard R. Leo

Array ( [id] => 12766270 [patent_doc_number] => 20180147258 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-31 [patent_title] => RECOMBINANT FUSION PROTEIN FORMULATION [patent_app_type] => utility [patent_app_number] => 15/513542 [patent_app_country] => US [patent_app_date] => 2015-09-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3854 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 222 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15513542 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14324105 [patent_doc_number] => 10293045 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-05-21 [patent_title] => Stable liquid formulations of recombinant fusion proteins [patent_app_type] => utility [patent_app_number] => 15/513537 [patent_app_country] => US [patent_app_date] => 2015-09-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3980 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 189 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15513537 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10662320 [patent_doc_number] => 20160008464 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-01-14 [patent_title] => 'Methods Of Treatment Of Pterygium Using An Anti-VEGF Agent' [patent_app_type] => utility [patent_app_number] => 14/861943 [patent_app_country] => US [patent_app_date] => 2015-09-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 9236 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14861943 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10635688 [patent_doc_number] => 09353182 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-05-31 [patent_title] => 'Anti-DLL3 antibodies' [patent_app_type] => utility [patent_app_number] => 14/859242 [patent_app_country] => US [patent_app_date] => 2015-09-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 54 [patent_figures_cnt] => 65 [patent_no_of_words] => 72418 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 58 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14859242 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15245251 [patent_doc_number] => 10508138 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-12-17 [patent_title] => Polypeptide capable of binding to vascular endothelial growth factor, and use thereof [patent_app_type] => utility [patent_app_number] => 15/737937 [patent_app_country] => US [patent_app_date] => 2015-09-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 5 [patent_no_of_words] => 6994 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15737937 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14372493 [patent_doc_number] => 20190160159 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-30 [patent_title] => ACETYLCHOLINE RECEPTOR-SPECIFIC IMMUNOSUPPRESSIVE COMPOSITIONS AND METHODS OF TREATMENT OF MYASTHENIA GRAVIS [patent_app_type] => utility [patent_app_number] => 15/511363 [patent_app_country] => US [patent_app_date] => 2015-09-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15079 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15511363 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13750801 [patent_doc_number] => 10168338 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-01-01 [patent_title] => Methods of identifying modulators of sestrin-gator-2 interaction for modulating mTORC1 activity [patent_app_type] => utility [patent_app_number] => 15/511007 [patent_app_country] => US [patent_app_date] => 2015-09-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 36 [patent_figures_cnt] => 36 [patent_no_of_words] => 19963 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 188 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15511007 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15338895 [patent_doc_number] => 10525104 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-01-07 [patent_title] => Predictive and prognostic biomarkers related to anti-angiogenic therapy of metastatic colorectal cancer [patent_app_type] => utility [patent_app_number] => 15/509461 [patent_app_country] => US [patent_app_date] => 2015-09-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 5686 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 92 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15509461 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12015819 [patent_doc_number] => 09808506 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-11-07 [patent_title] => 'Compositions comprising semaphorins for the treatment of cancer and methods of selection thereof' [patent_app_type] => utility [patent_app_number] => 14/847025 [patent_app_country] => US [patent_app_date] => 2015-09-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 43 [patent_no_of_words] => 20508 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14847025 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13714371 [patent_doc_number] => 20170368140 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-12-28 [patent_title] => USES OF NEUREGULIN IN PREVENTING, TREATING OR DELAYING VENTRICULAR ARRHYTHMIA, AND COMPOSITION THEREOF [patent_app_type] => utility [patent_app_number] => 15/513939 [patent_app_country] => US [patent_app_date] => 2015-09-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5584 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15513939 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10476153 [patent_doc_number] => 20150361171 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-12-17 [patent_title] => 'ANTAGONIST ANTIBODIES DIRECTED AGAINST CALCITONIN GENE-RELATED PEPTIDE AND METHODS USING SAME' [patent_app_type] => utility [patent_app_number] => 14/841396 [patent_app_country] => US [patent_app_date] => 2015-08-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 39094 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14841396 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10554822 [patent_doc_number] => 09279018 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-03-08 [patent_title] => 'Antagonist antibodies directed against calcitonin gene-related peptide and methods using same' [patent_app_type] => utility [patent_app_number] => 14/841479 [patent_app_country] => US [patent_app_date] => 2015-08-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 39085 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14841479 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10628737 [patent_doc_number] => 09346881 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-05-24 [patent_title] => 'Antagonist antibodies directed against calcitonin gene-related peptide and methods using same' [patent_app_type] => utility [patent_app_number] => 14/841440 [patent_app_country] => US [patent_app_date] => 2015-08-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 39107 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14841440 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10554822 [patent_doc_number] => 09279018 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-03-08 [patent_title] => 'Antagonist antibodies directed against calcitonin gene-related peptide and methods using same' [patent_app_type] => utility [patent_app_number] => 14/841479 [patent_app_country] => US [patent_app_date] => 2015-08-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 39085 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14841479 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10554822 [patent_doc_number] => 09279018 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-03-08 [patent_title] => 'Antagonist antibodies directed against calcitonin gene-related peptide and methods using same' [patent_app_type] => utility [patent_app_number] => 14/841479 [patent_app_country] => US [patent_app_date] => 2015-08-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 39085 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14841479 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10554822 [patent_doc_number] => 09279018 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-03-08 [patent_title] => 'Antagonist antibodies directed against calcitonin gene-related peptide and methods using same' [patent_app_type] => utility [patent_app_number] => 14/841479 [patent_app_country] => US [patent_app_date] => 2015-08-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 39085 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14841479 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10806556 [patent_doc_number] => 20160152714 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-06-02 [patent_title] => 'SUBTYPES OF HUMANIZED ANTIBODY AGAINST INTERLEUKIN-6 RECEPTOR' [patent_app_type] => utility [patent_app_number] => 14/836813 [patent_app_country] => US [patent_app_date] => 2015-08-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 24 [patent_no_of_words] => 9036 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14836813 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10687333 [patent_doc_number] => 20160033478 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-02-04 [patent_title] => 'HEMOKININ-1 RECEPTOR AND HEMOKININ-1-DERIVED PEPTIDE' [patent_app_type] => utility [patent_app_number] => 14/823378 [patent_app_country] => US [patent_app_date] => 2015-08-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 11313 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14823378 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10784164 [patent_doc_number] => 20160130320 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-05-12 [patent_title] => 'MODIFIED CHIMERIC POLYPEPTIDES WITH IMPROVED PHARMACOKINETIC PROPERTIES' [patent_app_type] => utility [patent_app_number] => 14/822929 [patent_app_country] => US [patent_app_date] => 2015-08-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 55 [patent_figures_cnt] => 55 [patent_no_of_words] => 19857 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14822929 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10684380 [patent_doc_number] => 20160030521 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-02-04 [patent_title] => 'THERAPEUTIC AGENTS COMPRISING ELASTIN-LIKE PEPTIDES' [patent_app_type] => utility [patent_app_number] => 14/822512 [patent_app_country] => US [patent_app_date] => 2015-08-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 33 [patent_figures_cnt] => 33 [patent_no_of_words] => 69097 [patent_no_of_claims] => 32 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14822512 [rel_patent_id] =>[rel_patent_doc_number] =>)